Psychiatry

Brexpiprazole and sertraline showed promise for PTSD treatment in a recent study. Lead author, Lori Davis, MD, discusses clinical findings, treatment guidelines, and future research directions.

Data showed that brexpiprazole plus sertraline significantly improved PTSD symptoms vs sertraline alone. Lead author, Lori Davis, MD, discusses more.

Findings on the efficacy of treatments for MDD include the favorable effects of exercise, of CBT, and the robust outcomes of ECT among neuromodulatory modalities.

The approval of esketamine follows an FDA Priority Review and is based on data showing that esketamine alone demonstrated rapid and superior improvement in depressive symptoms compared with placebo.

Your daily dose of the clinical news you may have missed.

A new analysis of patient reported outcomes from the PATHFINDER study indicate the potential clinical benefit of early cancer detection.

The acquisition brings lumateperone, known as Caplyta, and the clinical-stage agent ITI-1284, for generalized anxiety disorder and Alzheimer's agitation, into the J&J fold.

Your daily dose of the clinical news you may have missed.

An earlier phase 2 study found statistically significant improvement of MDD in female participants.

The adcomm meeting is expected to happen in the first half of 2025, and means the FDA expects to miss the target PDUFA date.

The failure of the novel kappa opioid receptor antagonist to best placebo in the first of triplicate phase 3 studies has Neumora concerned but not deterred.

Daily step counts of 5000 or more corresponded with fewer depressive symptoms, according to a recent systematic review and meta-analysis.

Substances of choice used in the previous 12 months were alcohol, nicotine vaping, and cannabis but the trends among the 8th, 10th, and 12th graders are very encouraging.

In the largest twin-sibling study to date of the inherited biological risk of PTSD, researchers found additive genetic and unique environmental effects contributed to the disorder.

New findings highlight the potential of this combination therapy as a new option for people with PTSD who have not responded to standard treatments.

A phase 1b and Phase 2 study are up next for the novel potential MDD treatment.

Intra-Cellular Therapies submitted an sNDA to the FDA for lumateperone for the treatment of MDD in adults as as adjunctive therapy to antidepressants.

Your daily dose of the clinical news you may have missed.

Approximately 70% of US adults surveyed hope their primary care clinician will ask about their mental health during an appointment, regardless of the presenting issue.

Your daily dose of the clinical news you may have missed.

Your daily dose of the clinical news you may have missed.

The FDA warnings were intended to increase physician monitoring for suicidal thoughts and behaviors but have had dramatic unintended consequences.

Your daily dose of the clinical news you may have missed.

Findings from a systematic review and meta-analysis showed 1 in 3 youth with chronic pain were diagnosed with anxiety and 1 in 8 were diagnosed with depression.

A 14% increase in the rates of primary care safety planning within 2 weeks of a negative screening was associated 25% drop in the rate of attempted suicides.

Cobenfy, previously KarXT, is the first new agent with a novel mechanism of action for schizophrenia in more than 50 years, according to BMS.

Your daily dose of the clinical news you may have missed.

In a study of persons with moderate-to-severe atopic dermatitis, lebrikizumab monotherapy for 16 weeks resulted in improved quality of life and mental health.

Your daily dose of the clinical news you may have missed.

In a study of adolescents with obesity, symptoms of depression and eating disorders decreased over the course of a 52-week intensive behavioral intervention.